We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

6 hedge funds and large institutions have $1.24M invested in Verve Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 169 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

81.59% less ownership

Funds ownership: 81.84% → 0.26% (-82%)

97% less funds holding

Funds holding: 175 → 6 (-169)

100% less capital invested

Capital invested by funds: $819M → $1.24M (-$818M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 169

Holders
6
Holders Change
-169
Holders Change %
-96.57%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
169
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$955K
2
IA
IFP Advisors
Florida
+$4.29K

Top Sellers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
-$137M
2
BlackRock
BlackRock
New York
-$82.6M
3
PCM
Pentwater Capital Management
Florida
-$75.5M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$47.1M
5
CC
Casdin Capital
New York
-$46M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
51
American Century Companies
Missouri
– -$1.9M -169,168 Closed
Invesco
52
Invesco
Georgia
– -$1.61M -143,445 Closed
Millennium Management
53
Millennium Management
New York
– -$1.55M -138,224 Closed
CCM
54
Chicago Capital Management
Illinois
– -$1.41M -125,377 Closed
FT
55
Fiduciary Trust
Massachusetts
– -$1.35M -120,000 Closed
Swiss National Bank
56
Swiss National Bank
Switzerland
– -$1.24M -110,200 Closed
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
– -$1.18M -104,721 Closed
Ameriprise
58
Ameriprise
Minnesota
– -$1.17M -103,955 Closed
GLF
59
Groupe la Francaise
France
– -$1.07M -95,400 Closed
Mirae Asset Global ETFs Holdings
60
Mirae Asset Global ETFs Holdings
Hong Kong
– -$973K -86,613 Closed
GCL
61
Glazer Capital LLC
New York
– -$930K -82,842 Closed
Susquehanna International Group
62
Susquehanna International Group
Pennsylvania
– -$925K -82,365 Closed
Simplex Trading
63
Simplex Trading
Illinois
– -$911K -81,129 Closed
SFI
64
Susquehanna Fundamental Investments
Pennsylvania
– -$898K -80,000 Closed
Rafferty Asset Management
65
Rafferty Asset Management
New York
– -$845K -75,235 Closed
Stifel Financial
66
Stifel Financial
Missouri
– -$843K -75,059 Closed
Los Angeles Capital Management
67
Los Angeles Capital Management
California
– -$776K -69,083 Closed
AllianceBernstein
68
AllianceBernstein
Tennessee
– -$765K -68,100 Closed
Legal & General Group
69
Legal & General Group
United Kingdom
– -$750K -66,825 Closed
CIEC
70
Crédit Industriel et Commercial
France
– -$714K -63,600 Closed
RC
71
Rangeley Capital
Connecticut
– -$696K -62,000 Closed
Balyasny Asset Management
72
Balyasny Asset Management
Illinois
– -$640K -57,032 Closed
Deutsche Bank
73
Deutsche Bank
Germany
– -$575K -51,180 Closed
MAM
74
Martingale Asset Management
Massachusetts
– -$565K -50,350 Closed
GAA
75
Green Alpha Advisors
Colorado
– -$562K -50,016 Closed
1 2
3
4 5

VERV Hedge Fund Activity: Q3 2025 in Review

6 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2025, worth a combined $1.24M — down 100% from $819M a quarter earlier.

Sellers outnumbered buyers: 169 funds closed out of VERV and 0 opened new positions — a net loss of 169 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was XTX Topco, adding an estimated $955K. The largest seller was Alphabet Inc, exiting entirely with an estimated $137M sold.

  • 6 institutional investors held Verve Therapeutics (VERV) as of Q3 2025, down from 175 in Q2 2025.
  • Funds reported $1.24M of Verve Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Verve Therapeutics positions in Q3 2025 and 169 closed out, a net change of -169 holders.
  • The largest Verve Therapeutics buyer in Q3 2025 was XTX Topco, an estimated $955K added.
  • The largest Verve Therapeutics seller in Q3 2025 was Alphabet Inc, an estimated $137M sold.

Based on aggregated 13F filings for Q3 2025.